Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Harvard Bioscience (HBIO) and Tilray (TLRY).
Harvard Bioscience (HBIO)
Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Harvard Bioscience today and set a price target of $4.00. The company’s shares closed last Monday at $3.09.
According to TipRanks.com, Jackson is a 1-star analyst with an average return of -1.9% and a 47.6% success rate. Jackson covers the Healthcare sector, focusing on stocks such as Staar Surgical Company, Flexion Therapeutics, and CNS Pharmaceuticals.
Harvard Bioscience has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.
See today’s analyst top recommended stocks >>
Tilray (TLRY)
In a report released today, Christopher Carey from Merrill Lynch reiterated a Hold rating on Tilray, with a price target of $20.00. The company’s shares closed last Monday at $14.85, close to its 52-week low of $14.00.
According to TipRanks.com, Carey is a 1-star analyst with an average return of -6.0% and a 45.2% success rate. Carey covers the Healthcare sector, focusing on stocks such as Aurora Cannabis, Aphria, and HEXO.
Currently, the analyst consensus on Tilray is a Hold with an average price target of $16.25, implying a 6.6% upside from current levels. In a report issued on February 24, Cowen & Co. also downgraded the stock to Hold with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TLRY:
